Lidocaine in bronchoalveolar lavage fluid (BALF) is an inhibitor of eosinophil-active cytokines

T. Ohnishi, H. Kita, A. N. Mayeno, S. Okada, Sanjiv Sur, D. H. Broide, G. J. Gleich

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Eosinophils and eosinophil granule proteins may play an important role in the pathogenesis of asthma. BALF from 40 patients with symptomatic asthma were analysed for cytokine activity by the eosinophil survival assay. BALF from 15 patients showed increased survival activity. Survival activities in BALF from four of these patients were almost completely blocked by anti-IL-5 MoAb, and the remaining activities were blocked by anti-granulocyte-macrophage colony-stimulating factor (GM-CSF), anti-IL-3 antibody, or both. Surprisingly, BALF samples from the other 25 patients decreased eosinophil viabilities below the levels of medium control. The inhibitory factor in these BALF was of low molecular weight, was heat-stable, was largely overcome by excess exogenously added cytokines, and was positively correlated with the concentrations of lidocaine in the BALF. Lidocaine itself inhibited eosinophil survival at concentrations less than those present in the BALF. These findings indicate that lidocaine is an inhibitor of cytokines in the eosinophil survival assay, and they suggest the need for caution in analyses of BALF containing lidocaine or other local anaesthetics.

Original languageEnglish (US)
Pages (from-to)325-331
Number of pages7
JournalClinical and Experimental Immunology
Volume104
Issue number2
StatePublished - 1996
Externally publishedYes

Fingerprint

Bronchoalveolar Lavage Fluid
Lidocaine
Eosinophils
Cytokines
Eosinophil Granule Proteins
Asthma
Survival
Interleukin-3
Interleukin-5
Granulocyte-Macrophage Colony-Stimulating Factor
Local Anesthetics
Hot Temperature
Molecular Weight
Antibodies

Keywords

  • Bronchial asthma
  • Bronchoalveolar lavage fluid
  • Eosinophil survival activity
  • IL-5 lidocaine

ASJC Scopus subject areas

  • Immunology

Cite this

Ohnishi, T., Kita, H., Mayeno, A. N., Okada, S., Sur, S., Broide, D. H., & Gleich, G. J. (1996). Lidocaine in bronchoalveolar lavage fluid (BALF) is an inhibitor of eosinophil-active cytokines. Clinical and Experimental Immunology, 104(2), 325-331.

Lidocaine in bronchoalveolar lavage fluid (BALF) is an inhibitor of eosinophil-active cytokines. / Ohnishi, T.; Kita, H.; Mayeno, A. N.; Okada, S.; Sur, Sanjiv; Broide, D. H.; Gleich, G. J.

In: Clinical and Experimental Immunology, Vol. 104, No. 2, 1996, p. 325-331.

Research output: Contribution to journalArticle

Ohnishi, T, Kita, H, Mayeno, AN, Okada, S, Sur, S, Broide, DH & Gleich, GJ 1996, 'Lidocaine in bronchoalveolar lavage fluid (BALF) is an inhibitor of eosinophil-active cytokines', Clinical and Experimental Immunology, vol. 104, no. 2, pp. 325-331.
Ohnishi, T. ; Kita, H. ; Mayeno, A. N. ; Okada, S. ; Sur, Sanjiv ; Broide, D. H. ; Gleich, G. J. / Lidocaine in bronchoalveolar lavage fluid (BALF) is an inhibitor of eosinophil-active cytokines. In: Clinical and Experimental Immunology. 1996 ; Vol. 104, No. 2. pp. 325-331.
@article{6012f04ffe004ebcb041ca327c8bbbc5,
title = "Lidocaine in bronchoalveolar lavage fluid (BALF) is an inhibitor of eosinophil-active cytokines",
abstract = "Eosinophils and eosinophil granule proteins may play an important role in the pathogenesis of asthma. BALF from 40 patients with symptomatic asthma were analysed for cytokine activity by the eosinophil survival assay. BALF from 15 patients showed increased survival activity. Survival activities in BALF from four of these patients were almost completely blocked by anti-IL-5 MoAb, and the remaining activities were blocked by anti-granulocyte-macrophage colony-stimulating factor (GM-CSF), anti-IL-3 antibody, or both. Surprisingly, BALF samples from the other 25 patients decreased eosinophil viabilities below the levels of medium control. The inhibitory factor in these BALF was of low molecular weight, was heat-stable, was largely overcome by excess exogenously added cytokines, and was positively correlated with the concentrations of lidocaine in the BALF. Lidocaine itself inhibited eosinophil survival at concentrations less than those present in the BALF. These findings indicate that lidocaine is an inhibitor of cytokines in the eosinophil survival assay, and they suggest the need for caution in analyses of BALF containing lidocaine or other local anaesthetics.",
keywords = "Bronchial asthma, Bronchoalveolar lavage fluid, Eosinophil survival activity, IL-5 lidocaine",
author = "T. Ohnishi and H. Kita and Mayeno, {A. N.} and S. Okada and Sanjiv Sur and Broide, {D. H.} and Gleich, {G. J.}",
year = "1996",
language = "English (US)",
volume = "104",
pages = "325--331",
journal = "Clinical and Experimental Immunology",
issn = "0009-9104",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Lidocaine in bronchoalveolar lavage fluid (BALF) is an inhibitor of eosinophil-active cytokines

AU - Ohnishi, T.

AU - Kita, H.

AU - Mayeno, A. N.

AU - Okada, S.

AU - Sur, Sanjiv

AU - Broide, D. H.

AU - Gleich, G. J.

PY - 1996

Y1 - 1996

N2 - Eosinophils and eosinophil granule proteins may play an important role in the pathogenesis of asthma. BALF from 40 patients with symptomatic asthma were analysed for cytokine activity by the eosinophil survival assay. BALF from 15 patients showed increased survival activity. Survival activities in BALF from four of these patients were almost completely blocked by anti-IL-5 MoAb, and the remaining activities were blocked by anti-granulocyte-macrophage colony-stimulating factor (GM-CSF), anti-IL-3 antibody, or both. Surprisingly, BALF samples from the other 25 patients decreased eosinophil viabilities below the levels of medium control. The inhibitory factor in these BALF was of low molecular weight, was heat-stable, was largely overcome by excess exogenously added cytokines, and was positively correlated with the concentrations of lidocaine in the BALF. Lidocaine itself inhibited eosinophil survival at concentrations less than those present in the BALF. These findings indicate that lidocaine is an inhibitor of cytokines in the eosinophil survival assay, and they suggest the need for caution in analyses of BALF containing lidocaine or other local anaesthetics.

AB - Eosinophils and eosinophil granule proteins may play an important role in the pathogenesis of asthma. BALF from 40 patients with symptomatic asthma were analysed for cytokine activity by the eosinophil survival assay. BALF from 15 patients showed increased survival activity. Survival activities in BALF from four of these patients were almost completely blocked by anti-IL-5 MoAb, and the remaining activities were blocked by anti-granulocyte-macrophage colony-stimulating factor (GM-CSF), anti-IL-3 antibody, or both. Surprisingly, BALF samples from the other 25 patients decreased eosinophil viabilities below the levels of medium control. The inhibitory factor in these BALF was of low molecular weight, was heat-stable, was largely overcome by excess exogenously added cytokines, and was positively correlated with the concentrations of lidocaine in the BALF. Lidocaine itself inhibited eosinophil survival at concentrations less than those present in the BALF. These findings indicate that lidocaine is an inhibitor of cytokines in the eosinophil survival assay, and they suggest the need for caution in analyses of BALF containing lidocaine or other local anaesthetics.

KW - Bronchial asthma

KW - Bronchoalveolar lavage fluid

KW - Eosinophil survival activity

KW - IL-5 lidocaine

UR - http://www.scopus.com/inward/record.url?scp=0029892145&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029892145&partnerID=8YFLogxK

M3 - Article

C2 - 8625528

AN - SCOPUS:0029892145

VL - 104

SP - 325

EP - 331

JO - Clinical and Experimental Immunology

JF - Clinical and Experimental Immunology

SN - 0009-9104

IS - 2

ER -